Research ExplorerPublicationsSurvival of Testicular Pure Embryonal Carcinoma vs. Mixed Ge...

Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages

Standard

Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages. / Cano Garcia, Cristina; Panunzio, Andrea; Tappero, Stefano; Piccinelli, Mattia Luca; Barletta, Francesco; Incesu, Reha-Baris; Law, Kyle W; Scheipner, Lukas; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F; Tilki, Derya; Briganti, Alberto; De Cobelli, Ottavio; Terrone, Carlo; Antonelli, Alessandro; Banek, Severine; Kluth, Luis A; Chun, Felix K H; Karakiewicz, Pierre I.

In: MEDICINA-LITHUANIA, Vol. 59, No. 3, 451, 24.02.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cano Garcia, C, Panunzio, A, Tappero, S, Piccinelli, ML, Barletta, F, Incesu, R-B, Law, KW, Scheipner, L, Tian, Z, Saad, F, Shariat, SF, Tilki, D, Briganti, A, De Cobelli, O, Terrone, C, Antonelli, A, Banek, S, Kluth, LA, Chun, FKH & Karakiewicz, PI 2023, 'Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages', MEDICINA-LITHUANIA, vol. 59, no. 3, 451. https://doi.org/10.3390/medicina59030451

APA

Cano Garcia, C., Panunzio, A., Tappero, S., Piccinelli, M. L., Barletta, F., Incesu, R-B., Law, K. W., Scheipner, L., Tian, Z., Saad, F., Shariat, S. F., Tilki, D., Briganti, A., De Cobelli, O., Terrone, C., Antonelli, A., Banek, S., Kluth, L. A., Chun, F. K. H., & Karakiewicz, P. I. (2023). Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages. MEDICINA-LITHUANIA, 59(3), [451]. https://doi.org/10.3390/medicina59030451

Vancouver

Cano Garcia C, Panunzio A, Tappero S, Piccinelli ML, Barletta F, Incesu R-B et al. Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages. MEDICINA-LITHUANIA. 2023 Feb 24;59(3). 451. https://doi.org/10.3390/medicina59030451

Bibtex

@article{12f928d454474b41afc2ce63108e010b,
title = "Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages",
abstract = "Background and Objectives: The impact of pure histological subtypes in testicular non-seminoma germ cell tumors on survival, specifically regarding pure embryonal carcinoma, is not well established. Therefore, this study aimed to test for differences between pure embryonal carcinoma and mixed germ cell tumor patients within stages I, II and III in a large population-based database. Materials and Methods: We relied on the Surveillance, Epidemiology and End Results (SEER) database (2004-2019) to identify testicular pure embryonal carcinoma vs. mixed germ cell tumor patients. Cumulative incidence plots depicted cancer-specific mortality that represented the main endpoint of interest. Multivariable competing risks regression models tested for differences between pure embryonal carcinoma and mixed germ cell tumor patients in analyses addressing cancer-specific mortality and adjusted for other-cause mortality. Results: Of 11,223 patients, 2473 (22%) had pure embryonal carcinoma. Pure embryonal carcinoma patients exhibited lower cancer-specific mortality relative to their mixed germ cell tumor counterparts for both stage III (13.9 vs. 19.4%; p < 0.01) and stage II (0.5 vs. 3.4%, p < 0.01), but not in stage I (0.9 vs. 1.6%, p = 0.1). In multivariable competing risks regression models, pure embryonal carcinoma exhibited more favorable cancer-specific mortality than mixed germ cell tumor in stage III (hazard ratio 0.71, p = 0.01) and stage II (hazard ratio 0.11, p < 0.01). Conclusions: Pure embryonal carcinoma exhibits a more favorable cancer-specific mortality profile relative to mixed germ cell tumor in stage II and III testicular cancers. Consequently, the presence of mixed germ cell tumor elements may be interpreted as a risk factor for cancer-specific survival.",
keywords = "Male, Humans, Carcinoma, Embryonal/pathology, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Risk Factors",
author = "{Cano Garcia}, Cristina and Andrea Panunzio and Stefano Tappero and Piccinelli, {Mattia Luca} and Francesco Barletta and Reha-Baris Incesu and Law, {Kyle W} and Lukas Scheipner and Zhe Tian and Fred Saad and Shariat, {Shahrokh F} and Derya Tilki and Alberto Briganti and {De Cobelli}, Ottavio and Carlo Terrone and Alessandro Antonelli and Severine Banek and Kluth, {Luis A} and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
year = "2023",
month = feb,
day = "24",
doi = "10.3390/medicina59030451",
language = "English",
volume = "59",
journal = "MEDICINA-LITHUANIA",
issn = "1010-660X",
publisher = "Kauno Medicinos Universitetas",
number = "3",

}

RIS

TY - JOUR

T1 - Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages

AU - Cano Garcia, Cristina

AU - Panunzio, Andrea

AU - Tappero, Stefano

AU - Piccinelli, Mattia Luca

AU - Barletta, Francesco

AU - Incesu, Reha-Baris

AU - Law, Kyle W

AU - Scheipner, Lukas

AU - Tian, Zhe

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Tilki, Derya

AU - Briganti, Alberto

AU - De Cobelli, Ottavio

AU - Terrone, Carlo

AU - Antonelli, Alessandro

AU - Banek, Severine

AU - Kluth, Luis A

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

PY - 2023/2/24

Y1 - 2023/2/24

N2 - Background and Objectives: The impact of pure histological subtypes in testicular non-seminoma germ cell tumors on survival, specifically regarding pure embryonal carcinoma, is not well established. Therefore, this study aimed to test for differences between pure embryonal carcinoma and mixed germ cell tumor patients within stages I, II and III in a large population-based database. Materials and Methods: We relied on the Surveillance, Epidemiology and End Results (SEER) database (2004-2019) to identify testicular pure embryonal carcinoma vs. mixed germ cell tumor patients. Cumulative incidence plots depicted cancer-specific mortality that represented the main endpoint of interest. Multivariable competing risks regression models tested for differences between pure embryonal carcinoma and mixed germ cell tumor patients in analyses addressing cancer-specific mortality and adjusted for other-cause mortality. Results: Of 11,223 patients, 2473 (22%) had pure embryonal carcinoma. Pure embryonal carcinoma patients exhibited lower cancer-specific mortality relative to their mixed germ cell tumor counterparts for both stage III (13.9 vs. 19.4%; p < 0.01) and stage II (0.5 vs. 3.4%, p < 0.01), but not in stage I (0.9 vs. 1.6%, p = 0.1). In multivariable competing risks regression models, pure embryonal carcinoma exhibited more favorable cancer-specific mortality than mixed germ cell tumor in stage III (hazard ratio 0.71, p = 0.01) and stage II (hazard ratio 0.11, p < 0.01). Conclusions: Pure embryonal carcinoma exhibits a more favorable cancer-specific mortality profile relative to mixed germ cell tumor in stage II and III testicular cancers. Consequently, the presence of mixed germ cell tumor elements may be interpreted as a risk factor for cancer-specific survival.

AB - Background and Objectives: The impact of pure histological subtypes in testicular non-seminoma germ cell tumors on survival, specifically regarding pure embryonal carcinoma, is not well established. Therefore, this study aimed to test for differences between pure embryonal carcinoma and mixed germ cell tumor patients within stages I, II and III in a large population-based database. Materials and Methods: We relied on the Surveillance, Epidemiology and End Results (SEER) database (2004-2019) to identify testicular pure embryonal carcinoma vs. mixed germ cell tumor patients. Cumulative incidence plots depicted cancer-specific mortality that represented the main endpoint of interest. Multivariable competing risks regression models tested for differences between pure embryonal carcinoma and mixed germ cell tumor patients in analyses addressing cancer-specific mortality and adjusted for other-cause mortality. Results: Of 11,223 patients, 2473 (22%) had pure embryonal carcinoma. Pure embryonal carcinoma patients exhibited lower cancer-specific mortality relative to their mixed germ cell tumor counterparts for both stage III (13.9 vs. 19.4%; p < 0.01) and stage II (0.5 vs. 3.4%, p < 0.01), but not in stage I (0.9 vs. 1.6%, p = 0.1). In multivariable competing risks regression models, pure embryonal carcinoma exhibited more favorable cancer-specific mortality than mixed germ cell tumor in stage III (hazard ratio 0.71, p = 0.01) and stage II (hazard ratio 0.11, p < 0.01). Conclusions: Pure embryonal carcinoma exhibits a more favorable cancer-specific mortality profile relative to mixed germ cell tumor in stage II and III testicular cancers. Consequently, the presence of mixed germ cell tumor elements may be interpreted as a risk factor for cancer-specific survival.

KW - Male

KW - Humans

KW - Carcinoma, Embryonal/pathology

KW - Neoplasms, Germ Cell and Embryonal

KW - Testicular Neoplasms

KW - Risk Factors

U2 - 10.3390/medicina59030451

DO - 10.3390/medicina59030451

M3 - SCORING: Journal article

C2 - 36984452

VL - 59

JO - MEDICINA-LITHUANIA

JF - MEDICINA-LITHUANIA

SN - 1010-660X

IS - 3

M1 - 451

ER -